Clinical Trials Sponsored by BioInvent International AB

Total 46 results

BioInvent International AB

Active, not recruiting

BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors (CONTRAST)

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | HER2-positive Metastatic Breast Cancer

Spain, United Kingdom, Germany
BioInvent International AB

Terminated

A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma

Multiple Myeloma

United States
BioInvent International AB

Completed

A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma

Multiple Myeloma

Denmark, Belgium, United States, Sweden
BioInvent International AB

Recruiting

A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma

Indolent B-Cell Non-Hodgkin Lymphoma

Spain, United States, Brazil, Sweden, Germany, Poland
BioInvent International AB

Terminated

A Phase II Study of BI-505 in Smoldering Multiple Myeloma

Smoldering Multiple Myeloma

Sweden
ThromboGenics
BioInvent International AB

Completed

Single IV Administration of TB-402 for Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery

Prophylaxis of Venous Thromboembolic Events

Austria, Netherlands, Belgium, Bulgaria, Hungary, Latvia, Poland, Russian Federation, Ukraine
ThromboGenics
BioInvent International AB

Completed

Effects of LMWH in Healthy Subjects Treated With TB-402 and Effects of TB-402 in Healthy Subjects Treated With Warfarin

Healthy

Denmark
ThromboGenics
BioInvent International AB

Completed

Effect of Recombinant FVIII in Healthy Male Subjects Treated With TB-402

Healthy

Denmark
BioInvent International AB
Oxurion

Completed

Phase I Study on Monoclonal Antibody TB-403 Directed Against PlGF in Patients With Solid Tumours

Solid Tumors

Denmark
ThromboGenics
BioInvent International AB

Completed

A Phase I Study of Monoclonal Antibody TB-402 in Healthy Male Volunteers

Healthy

Denmark
ThromboGenics
Covance; BioInvent International AB

Completed

Single Intravenous Administration of TB-402 for the Prophylaxis of Venous Thromboembolic Events (VTE) After Total Knee Replacement Surgery

Total Knee Replacement Surgery

Israel, Romania, Bulgaria, Latvia, Poland, Russian Federation, Ukraine
Genentech, Inc.
BioInvent International AB

Completed

A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)

Atherosclerosis

United States, Canada
BioInvent International AB
Genentech, Inc.

Completed

Bioavailability Study of MLDL1278A After Subcutaneous and Intravenous Administration in Healthy Subjects

Healthy

United Kingdom
BioInvent International AB
Merck Sharp & Dohme LLC

Recruiting

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

Advanced Malignancies

United Kingdom, Denmark, Hungary, Russian Federation
Cancer Research UK
BioInvent International AB; Bloodwise

Completed

BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia

B-cell Lymphoma | Waldenström Macroglobulinemia | Chronic Lymphocytic Leukaemia

United Kingdom
BioInvent International AB
Merck Sharp & Dohme LLC

Recruiting

BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors

Hepatocellular Carcinoma | Non Small Cell Lung Cancer | Solid Tumors

Spain, Denmark, Poland, Sweden
BioInvent International AB
Merck Sharp & Dohme LLC

Recruiting

A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (KEYNOTE-A04)

Solid Tumor, Adult

United States, Sweden
Transgene
Merck Sharp & Dohme LLC; BioInvent International AB

Recruiting

A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors

Melanoma | Soft Tissue Sarcoma | Non Small Cell Lung Cancer | Metastatic Cancer | Triple Negative Breast Cancer | Merkel Cell Carcinoma

France, Belgium
Occlutech International AB

Recruiting

PMCF Study to Evaluate Efficacy, Safety of the Occlutech PDA Occluder in Patients With Patent Ductus Arteriosus Defects

Patent Ductus Arteriosus

Tunisia, Turkey, Italy, Pakistan, United Kingdom
Occlutech International AB

Recruiting

ACCESS Registry: A Post Market Follow-up Study to Monitor the Safety, Performance and Usability of Occlutech Accessory Medical Devices

Heart Diseases

Turkey, Germany
Occlutech International AB

Recruiting

Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion (OCCLUFLEX)

Stroke | Patent Foramen Ovale

United States, Denmark, Canada, Netherlands, Germany, United Kingdom, Finland
Occlutech International AB

Active, not recruiting

A Multicenter, International, Follow-up Study to Monitor the Efficacy and Safety of the Occlutech® PmVSD Occluder in Patients With Perimembranous Ventricular Septal Defects

Perimembranous Ventricular Septal Defect

Thailand, Germany, Ireland, Vietnam
Occlutech International AB

Completed

Follow-up Registry to Monitor the Efficacy and Safety of the Occlutech PLD Device

Mitral Paravalvular Leaks (PVL) | Aortic Paravalvular Leaks (PVL)

Italy
Occlutech International AB

Recruiting

Follow-up Study to Monitor the Efficacy and Safety of the Occlutech® mVSD Cases (mVSD Registry)

Muscular Ventricular Septal Defect

Turkey
Occlutech International AB

Recruiting

The Prophet Trial -Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator (AFR) in Patients With Pulmonary Hypertension (AFR-Prophet)

Pulmonary Hypertension

Germany, Netherlands, Poland, Turkey
Occlutech International AB

Active, not recruiting

Flow Regulation by Opening the SepTum in Patients With Heart Failure; a Prospective, Randomized, Sham-controlled, Double-blind, Global Multicenter Study (FROST-HF)

Heart Failure With Preserved Ejection Fraction (HFpEF) | Heart Failure With Reduced Ejection Fraction (HFrEF)

United States
Occlutech International AB

Completed

Occlutech Septal Occluder (Figulla Flex II) Study

Secundum Atrial Septal Defects
Occlutech International AB

Completed

Prospective, Non-randomized, Safety and Efficacy Study of a New Occluder Design for Minimally Invasive Closure of the Left Atrial Appendage (LAA) in Patients With Atrial Fibrillation (OLAAC)

Atrial Fibrillation

Germany, United Kingdom
Occlutech International AB

Recruiting

The AFteR Registry - Follow-up Study to Monitor the Efficacy and Safety of the Occlutech AFR in Heart Failure Patients

Heart Failure

France, Germany
Occlutech International AB

Completed

Safety and Effectiveness Study With a New PDA Occluder for Closure of Patent Ductus Arteriosus

Patent Ductus Arteriosus

Malaysia, Vietnam
Occlutech International AB

Active, not recruiting

The PROOF Trial - Prospective, Open-label, Multicenter, Non-randomized Investigation on Percutaneous Patent Foramen Ovale (PFO) Closure Using the Occlutech PFO Occluder to Prevent Recurrence of Stroke in Patients With Cryptogenic Stroke and High Risk PFO (PROOF)

Stroke | PFO - Patent Foramen Ovale

France, Germany, Italy, Canada
Occlutech International AB

Completed

The Prelieve Trial - Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator (AFR) in Heart Failure Patients (PRELIEVE)

Heart Failure | Heart Failure Low Output

Germany, Turkey, Belgium
OrtoWay AB
MedPass International

Unknown

Study Assessing Safety and Performance of OrtoWell Distractor in Patients Undergoing Spinal Surgery

Spinal Surgery

Germany
IBD Column Therapies International AB

Completed

A Study to Evaluate a Leukapheresis Treatment in Patients With Ulcerative Colitis

Ulcerative Colitis

Sweden
Gabather AB
Smerud Medical Research International AS

Completed

Study of Ascending Single Oral Dose of GT-002 in Healthy Volunteers (GAB-001)

Safety and Tolerability

Finland
Rare Thyroid Therapeutics International AB
Vitaccess Ltd

Completed

MCT8 Deficiency Caregiver Study

Allan-Herndon-Dudley Syndrome | Monocarboxylate Transporter 8 (MCT8) Deficiency

United Kingdom
Air Liquide Santé International
Key2Compliance; NordicInfu Care AB

Recruiting

Clinical Investigation to Assess the Feasibility of a New Diabetes Management Program (ODIN)

Type 1 Diabetes

Sweden
Rare Thyroid Therapeutics International AB
Egetis Therapeutics; AnovoRx

Available

Expanded Access Program for Tiratricol in Patients With Monocarboxylate Transporter 8 Deficiency

Monocarboxylate Transporter 8 Deficiency | Allan-Herndon-Dudley Syndrome

United States
Rare Thyroid Therapeutics International AB
Erasmus Medical Center

Active, not recruiting

Triac Trial II in MCT8 Deficiency Patients

Allan-Herndon-Dudley Syndrome

United States, Netherlands, Czechia, Germany
ACO Hud Nordic AB
Smerud Medical Research International AS

Completed

A Randomised Trial of a Moisturising Cream in Preventing Recurrence of Hand Eczema

Hand Eczema

Norway
University of Sao Paulo
InCor Heart Institute; Occlutech International AB

Completed

Bronchoscopic Closure of Bronchopleural Fistulas With Occlutech Figulla ASD N Occluder Device

Bronchopleural Fistula

Brazil
Rare Thyroid Therapeutics International AB
Premier Research Group plc; Egetis Therapeutics

Recruiting

Withdrawal of Tiratricol Treatment in Males With Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency) (ReTRIACt)

Monocarboxylate Transporter 8 Deficiency | Allan-Herndon-Dudley Syndrome

United States, United Kingdom, Netherlands
PATH
International Centre for Diarrhoeal Disease Research, Bangladesh; Scandinavian...

Completed

Enterotoxigenic Escherichia Coli (ETEC) ETVAX Vaccine Trial in Bangladesh (ETVAX/dmLT)

Escherichia Coli Diarrhea

Bangladesh
Assistance Publique - Hôpitaux de Paris
Ministry of Health, France; W.L.Gore & Associates; Abbott; Centre Hospitalier St... and other collaborators

Not yet recruiting

PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years (CLOSE-2)

Patent Foramen Ovale | Cryptogenic Ischemic Stroke

France
Hans Törnblom
Karolinska University Hospital; Oslo University Hospital; Sahlgrenska University... and other collaborators

Completed

Mesalazine Treatment in IBS (The MIBS Study) (MIBS)

Irritable Bowel Syndrome

Sweden
Medical University of Graz
University of Leeds; Catholic University of the Sacred Heart; University of Manchester and other collaborators

Not yet recruiting

Kidney AI-enabled Care Transformation

Chronic Kidney Diseases

United Kingdom, Italy

Clinical Trials Sponsored by BioInvent International AB

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Russia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations